KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Change in Receivables (2016 - 2025)

Historic Change in Receivables for Biomarin Pharmaceutical (BMRN) over the last 17 years, with Q3 2025 value amounting to -$48.7 million.

  • Biomarin Pharmaceutical's Change in Receivables fell 16554.08% to -$48.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $34.8 million, marking a year-over-year decrease of 8156.61%. This contributed to the annual value of $57.9 million for FY2024, which is 6959.12% down from last year.
  • Latest data reveals that Biomarin Pharmaceutical reported Change in Receivables of -$48.7 million as of Q3 2025, which was down 16554.08% from $98.5 million recorded in Q2 2025.
  • In the past 5 years, Biomarin Pharmaceutical's Change in Receivables registered a high of $138.8 million during Q1 2023, and its lowest value of -$72.5 million during Q4 2024.
  • Moreover, its 5-year median value for Change in Receivables was $22.9 million (2021), whereas its average is $19.6 million.
  • As far as peak fluctuations go, Biomarin Pharmaceutical's Change in Receivables crashed by 29324.55% in 2021, and later skyrocketed by 4646229.51% in 2022.
  • Biomarin Pharmaceutical's Change in Receivables (Quarter) stood at -$61000.0 in 2021, then soared by 46462.3% to $28.3 million in 2022, then skyrocketed by 106.83% to $58.5 million in 2023, then tumbled by 224.02% to -$72.5 million in 2024, then surged by 32.81% to -$48.7 million in 2025.
  • Its last three reported values are -$48.7 million in Q3 2025, $98.5 million for Q2 2025, and $57.6 million during Q1 2025.